Make an Inquiry
Accelerating Staphylococcus Aureus Infection Drug Development

Methicillin-resistant Staphylococcus aureus (MRSA) infections present a critical and escalating challenge in global healthcare, marked by limited treatment options and rising resistance rates. Ace Therapeutics is dedicated to advancing the development of novel therapeutics targeting MRSA, leveraging deep expertise in infectious disease research and drug discovery. As a specialized partner in MRSA drug development, Ace Therapeutics offers a comprehensive suite of preclinical services encompassing target validation, lead optimization, and IND-enabling studies. Our scientific team combines extensive experience in microbiology and pharmacology with advanced in vitro and in vivo platforms specifically tailored for MRSA research. Rigorous adherence to regulatory standards ensures the generation of robust, translatable data to support successful clinical advancement. At Ace Therapeutics, our commitment is to accelerate the development of innovative anti-MRSA therapies, empowering our partners to address unmet medical needs and deliver impactful solutions to patients worldwide.

What is Staphylococcus Aureus InfectionTargets for Staphylococcus Aureus InfectionDrug Discovery and Development ServicesWhy Choose Us

What is Staphylococcus Aureus Infection

Staphylococcus aureus infection encompasses a spectrum of diseases caused by the Gram-positive bacterium Staphylococcus aureus. This versatile pathogen colonizes the skin and mucosal surfaces, employing virulence factors such as protein A, coagulase, and various toxins to evade immune defenses and invade tissues. The organism’s ability to develop resistance, particularly methicillin resistance (MRSA), complicates management and contributes to significant morbidity and mortality. S. aureus can cause conditions ranging from mild skin infections to severe systemic illnesses, including bacteremia, endocarditis, pneumonia, osteomyelitis, and toxin-mediated syndromes. Clinically, S. aureus infection may present as skin and soft tissue infections (e.g., abscesses, cellulitis), bloodstream infections, pneumonia, bone and joint infections, or toxin-mediated diseases like toxic shock syndrome. Diagnosis relies on clinical assessment and laboratory confirmation through culture of sterile site specimens, Gram staining, and biochemical or molecular testing to determine antibiotic susceptibility. Imaging may be required for deep-seated or metastatic infections. Treatment is guided by susceptibility profiles: methicillin-susceptible strains are managed with penicillinase-resistant penicillins (e.g., dicloxacillin, cloxacillin), while MRSA and resistant cases may require agents such as vancomycin, daptomycin, linezolid, or newer antibiotics like ceftaroline and levonadifloxacin. Timely diagnosis and appropriate therapy are essential to reduce complications and improve outcomes.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-948895-94-1-alalevonadifloxacin-mesylate-rec-inn alalevonadifloxacin mesylate (Rec INN) 948895-94-1 C22 H26 F N3 O5 . C H4 O3 S 527.563
img-154357-42-3-free-base371246-52-5-s-nadifloxacin-arginine-saltlevonadifloxacin-argin (S)-nadifloxacin arginine salt; levonadifloxacin arginine salt (Rec INNM) 154357-42-3 (free base); 371246-52-5 C19 H21 F N2 O4 . C6 H14 N4 O2 . H2 O 552.596
img-400827-46-5-ceftaroline-fosamil-acetate-prop-innm-usancephalos ceftaroline fosamil acetate (Prop INNM; USAN); cephalosporin Lorraine 400827-46-5 C22 H21 N8 O8 P S4 . C2 H4 O2 744.737
img-103060-53-3-daptomycin-rec-inn-usan-ban daptomycin (Rec INN; USAN; BAN) 103060-53-3 C72 H101 N17 O26 1620.671
img-165800-03-3-linezolid-prop-inn-usan linezolid (Prop INN; USAN) 165800-03-3 C16 H20 F N3 O4 337.346
img-104931-87-551025-85-5-free-base-arbekacin-sulfate-rec-innmhabekacin-sulfate arbekacin sulfate (Rec INNM); habekacin sulfate 104931-87-5; 51025-85-5 (free base) C22 H44 N6 O10 . H2 O4 S 650.697
img-1404-90-6-free-base1404-93-9-vancomycin-hydrochloride-rec-innm-usan-banm vancomycin hydrochloride (Rec INNM; USAN; BANM) 1404-90-6 (free base); 1404-93-9 C66 H75 Cl2 N9 O24 . Cl H 1485.715
img-unknown-dicloxacillin-sodium-monohydratesodium-dicloxacill dicloxacillin sodium monohydrate; sodium dicloxacillin monohydrate C19 H16 Cl2 N3 O5 S . Na . H2 O 510.323
img-61-72-3-free-acid642-78-4-cloxacillin-sodiumsodium-cloxacillin cloxacillin sodium; sodium cloxacillin 61-72-3 (free acid); 642-78-4 C19 H17 Cl N3 O5 S . Na . H2 O 475.878

Learn More

Targets for Staphylococcus Aureus Infection

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
16S Ribosomal protein
30S Ribosomal protein
50S Ribosomal protein
DNA topoisomerase IV (bacterial)
DNA gyrase (bacterial)
Penicillin-binding protein 2
monoamine oxidase A MAOA
Penicillin-binding protein (PBP) (bacterial)
Enoyl-(Acyl Carrier Protein) Reductase (Fabl)
Enoyl-ACP reductase FabL

Staphylococcus aureus (MRSA) relies on several essential molecular targets for survival, proliferation, and resistance to antibiotics. Key among these are ATP-dependent Clp protease proteolytic subunit (ClpP), which maintains protein quality control under stress; cell division protein FtsZ, a tubulin homolog critical for cytokinesis; DNA topoisomerase IV subunit A (parC), essential for chromosome segregation during replication; enoyl-ACP reductase (FabI/FabL), which catalyzes a vital step in fatty acid biosynthesis; and penicillin-binding protein 2 (PBP2), a central enzyme in cell wall synthesis. Each target plays a distinct role: ClpP degrades misfolded proteins, FtsZ orchestrates cell division, topoisomerase IV resolves DNA topology, FabI/FabL ensures membrane integrity, and PBP2 constructs the peptidoglycan cell wall. Disrupting these functions impairs bacterial viability and undermines the pathogen’s ability to withstand host defenses and antibiotic treatment. Therapeutically, these targets offer promising avenues for novel anti-staphylococcal agents. ClpP inhibitors, such as ADEP antibiotics, induce lethal proteolysis, while FtsZ and topoisomerase IV are validated targets of compounds like PC190723 and fluoroquinolones, respectively. Inhibition of FabI/FabL by agents such as triclosan or AFN-1252 disrupts membrane synthesis, and targeting PBP2 remains foundational in β-lactam therapy, despite resistance conferred by PBP2a in MRSA. Many inhibitors are in preclinical or clinical development, with some already in clinical use, underscoring the translational potential of these targets. Continued research into these molecular vulnerabilities is crucial for overcoming resistance and guiding the next generation of antibacterial therapies.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates discovery of therapies targeting Staphylococcus aureus, including methicillin-resistant strains (MRSA). We offer advanced screening platforms utilizing fluorescent and kynuramine-based assays to assess compound efficacy, focusing on key targets such as Monoamine Oxidase A. Our sensitive methods quantify bacterial inhibition, enzyme modulation, and resistance mechanisms, providing mechanistic insights. Critical pharmacological parameters, including IC-50, are measured to determine compound potency and guide lead optimization. This comprehensive approach enables rapid and robust evaluation of antimicrobial candidates, supporting informed decision-making in drug development against S. aureus infections.

Monoamine Oxidase A

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the fight against Infection, Staphylococcus aureus (Methicillin-resistant (MRSA)) through specialized expertise and unwavering commitment to excellence. Our team of seasoned professionals brings deep knowledge and experience in MRSA research and drug development, ensuring that every project benefits from the latest scientific insights and innovative approaches. Supported by advanced technology platforms, Ace Therapeutics is equipped to deliver comprehensive preclinical drug development services tailored to the unique challenges of MRSA therapeutics. Our proven track record of reliability and success in preclinical studies underscores our reputation as a trusted partner in the industry. We adhere to the highest quality standards and maintain strict regulatory compliance at every stage of development, giving our clients confidence in the integrity and safety of our processes. Above all, Ace Therapeutics is committed to making a meaningful impact in the field of MRSA therapeutics, working tirelessly to bring new and effective treatments closer to patients in need. Choose Ace Therapeutics for professionalism, reliability, and a genuine dedication to advancing infectious disease therapeutics.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Methicillin-resistant Staphylococcus aureus (MRSA) infections?

A: Preclinical research for MRSA poses several unique challenges, including the need to identify compounds with novel mechanisms of action to overcome existing resistance, the difficulty of replicating clinically relevant infection models, and the necessity to demonstrate efficacy against a broad range of MRSA strains. Additionally, optimizing pharmacokinetic and pharmacodynamic (PK/PD) profiles to ensure adequate tissue penetration, particularly in difficult-to-treat sites such as bone or biofilm-associated infections, is critical. Our company addresses these challenges by employing advanced in vitro and in vivo models that closely mimic human infection scenarios and by utilizing comprehensive strain panels during efficacy testing.

Q: What are the key regulatory considerations for preclinical development of anti-MRSA therapeutics?

A: Regulatory agencies such as the FDA and EMA require robust preclinical data to support the safety and efficacy of anti-MRSA candidates. This includes demonstrating in vitro activity against clinically relevant MRSA strains, comprehensive toxicology studies in at least two animal species, and well-designed in vivo efficacy models. Regulatory guidance also emphasizes the importance of addressing antimicrobial resistance development and cross-resistance potential. Our services are designed to ensure all preclinical studies adhere to Good Laboratory Practice (GLP) standards and regulatory expectations, facilitating a smooth transition to clinical development.

Q: What technical aspects should be considered in preclinical research for MRSA drug development?

A: Technical considerations include selecting appropriate MRSA strains for screening, developing robust in vitro assays to evaluate antibacterial activity, and establishing validated animal models that reflect human disease pathology. It is also important to assess the compound's ability to penetrate biofilms and target intracellular bacteria, as MRSA can persist in these niches. Our team leverages state-of-the-art microbiology, molecular biology, and imaging technologies to provide comprehensive characterization of candidate drugs, from mechanism of action studies to resistance profiling.

Q: What are the typical timeline and cost considerations for preclinical development of anti-MRSA drugs?

A: The preclinical phase for anti-MRSA drug candidates typically spans 18 to 36 months, depending on the complexity of the compound and the required studies. Costs can vary significantly, ranging from $2 million to $8 million, influenced by the extent of efficacy, toxicology, and ADME (absorption, distribution, metabolism, and excretion) studies. Our company offers tailored project management and budgeting, providing clients with detailed timelines and cost estimates, and optimizing study designs to reduce time and expense without compromising data quality.

Q: What are the critical success factors for preclinical development of drugs targeting MRSA infections?

A: Success in preclinical MRSA drug development hinges on several factors: early identification of compounds with novel and potent anti-MRSA activity, rigorous validation of efficacy in relevant infection models, thorough safety and toxicology assessments, and proactive management of resistance risk. Collaboration with experienced preclinical CROs, like our company, ensures access to specialized expertise, advanced technologies, and regulatory knowledge, all of which are essential for generating high-quality data and advancing candidates to clinical trials with confidence.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.